CK19 Promotes Ovarian Cancer Development by Impacting on Wnt/β-Catenin Pathway
Authors Lu Q, Qu H, Lou T, Liu C, Zhang Z
Received 18 December 2019
Accepted for publication 12 March 2020
Published 24 March 2020 Volume 2020:13 Pages 2421—2431
Checked for plagiarism Yes
Review by Single-blind
Peer reviewer comments 2
Editor who approved publication: Dr Carlos E Vigil
Qi Lu, Hong Qu, Tong Lou, Chongdong Liu, Zhenyu Zhang
Department of Obstetrics and Gynecology, Chao-yang Hospital, Capital Medical University, Beijing, People’s Republic of China
Correspondence: Zhenyu Zhang; Chongdong Liu
Department of Obstetrics and Gynecology, Beijing Chao-yang Hospital, Capital Medical University, 8 Gongtinanlu, Chaoyang District, Beijing 100020, People’s Republic of China
Tel +86 13801237287
Fax +86 10 85231507
Email firstname.lastname@example.org; email@example.com
Background: Epithelial ovarian cancer (EOC) is the most common type of ovarian cancer and is the most lethal gynecologic malignancy. Cytokeratin 19 (CK19) is a small type I cytokeratin. The aim of this study is to explore the functional role of CK19 and its underlying mechanism in EOC.
Methods: The expression levels of CK19 in EOC tissues were identified by Western blotting and RT-PCR assay. Transwell assay and CCK-8 proliferation assay were used to assess the invasion, migration and proliferation abilities of overexpressed or knockdown CK19 of ovarian cancer cells. We also detected the related genes of Wnt/β-catenin signal pathway, including β-catenin, TCF7, LEF1, c-MYC and cyclin D1 in the transfected ovarian cancer cells by Western blotting and RT-PCR assay.
Results: The results demonstrated that CK19 was upregulated in EOC tissue. CK19 was verified to promote the invasion, proliferation and migration of ovarian cancer cells. Additionally, CK19 activates the Wnt/β-catenin signaling pathway by upregulated β-catenin, TCF7, LEF1, c-MYC and cyclin D1.
Conclusions: In summary, this is the first study to investigate the role of CK19 in EOC. These findings provide a potential new therapeutic target for the clinical diagnosis and treatment of ovarian cancer.
Keywords: CK19, Wnt/β-catenin, ovarian cancer, SKOV3
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]